Cloudbreak Pharma Inc.
2592.HK
Hong Kong Stock Exchange1.29
HKD
-0.14
- -
ISIN
KYG2215S1084
Return %
Stock
S&P500
1Y
-77.95
19.99
3Y
-79.19
68.07
5Y
-79.19
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jinsong Ni
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8921 Research Drive Irvine CA United States of America 92618
- IPO Date
- Jul 2, 2025
- Website
- cloudbreakpharma.com
- Similar Companies
- Business
- Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company focused on developing novel, differentiated eye-care therapies for chronic ocular diseases; headquartered in Irvine, California, with primary listings on the Hong Kong Stock Exchange (ticker 2592.HK) and a corporate structure that encompasses in-house discovery, development, and potential commercialization of first-in-class and best-in-class ophthalmic medicines. The company maintains a diversified pipeline spanning multiple therapeutic areas within ophthalmology, emphasizing disease-modifying topical agents and biologic-conjugate approaches designed to address conditions such as pterygium, pinguecula, meibomian gland dysfunction, glaucoma-related surgical outcomes, and degenerative retinal diseases. Main products and services - CBT-001, a disease-modifying topical therapeutic for pterygium, currently advancing in Phase III with topline data anticipated in 2026; the program targets a broad, multi-billion-dollar addressable market and aims to redefine standard of care for pterygium management; CBT-001 embodies Cloudbreak’s core strategy of developing first-in-class or best-in-class ophthalmic drugs with meaningful clinical impact. - CBT-004, a therapy indicated for vascularized pinguecula, positioned as a Phase III-ready asset following regulatory alignment and End-of-Phase-2 discussions with the FDA to establish a clear development pathway; this program exemplifies the company’s emphasis on proliferative conjunctival diseases. - CBT-009, aimed at juvenile myopia, representing Cloudbreak’s expansion into refractive error modulation and pediatric ophthalmology. - CBT-006, CBT-199, CBT-145, CBT-007, CBT-011, and CBT-001/004 series assets addressing various anterior and posterior segment diseases, including presbyopia, corneal surface disorders, diabetic macular edema, and adjuvant strategies for surgical outcomes; collectively, these programs illustrate a broad pipeline from preclinical to late-stage development. - Discovery and development services in-house, including targeting, lead optimization, preclinical testing, and translational planning, with collaborations and potential partnerships to advance clinical programs toward regulatory approval and commercialization. Latest major company changes - Strategic pipeline updates and regulatory milestones in 2026, including public disclosures of Phase III progress for CBT-001 in pterygium and advancement of CBT-004 toward Phase III readiness after FDA alignment; these updates reflect aggressive clinical execution and a sharpened development path. - Corporate and regulatory filings noting headquarters and principal administrative updates, including moves in Hong Kong related to registered business operations and corporate disclosures; these changes indicate ongoing governance and compliance improvements aligned with global expansion. - Public communications detailing ongoing pipeline breadth and potential expansion into additional ocular indications, signaling a strategic pivot toward a diversified portfolio of high-value ophthalmic therapies and companion technologies; market updates emphasize the breadth of the company’s ocular disease focus and readiness for scalable development pathways. Additional context - Industry and segments: biotechnology and pharmaceutical development with a focus on ophthalmology, including drug discovery, preclinical and clinical development, regulatory strategy, and potential commercialization. - Target markets: global ophthalmology markets, with particular emphasis on pterygium, pinguecula, myopia, glaucoma-related interventions, and other anterior/posterior segment diseases. - Geographic operations: primary research and development activities in the United States, with international regulatory and potential commercialization considerations and listings in Hong Kong; Hong Kong regulatory filings indicate cross-border investor communication and compliance requirements; corporate notices reflect ongoing operational footprint in Asia-Pacific and North America. - Founding year and headquarters: established in 2015 with headquarters in Irvine, California, United States, and a listed corporate presence on the Hong Kong Exchange; this dual footprint supports cross-border fundraising, partnerships, and global clinical program management. - Subsidiaries/parent: Cloudbreak Pharma Inc. operates as the principal corporate entity, with regulatory and market disclosures reflecting its corporate structure and international status; presence and activity in Hong Kong suggest a registered IP and corporate entity network aligned with global capital markets. Note: This description integrates publicly disclosed information on Cloudbreak Pharma Inc.’s core products, clinical program status, and recent regulatory and strategic developments to present a comprehensive overview suitable for financial databases and investment research platforms. The company’s ongoing clinical program updates and Hong Kong regulatory filings are cited to reflect the latest available publicly reported milestones.